Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collplant Holdings ( (CLGN) ) has provided an update.
On February 26, 2026, CollPlant Biotechnologies announced that the Korean Patent Office has allowed a patent application covering key aspects of its photocurable dermal filler technology for the aesthetic market. The patent, which runs through 2039, protects a polymerizable rhCollagen- and hyaluronic acid-based formulation that is injected into sub-epidermal tissue and then light-activated in situ to form a supportive scaffold for structural tissue restoration and long-term contour stability.
Management described the allowance as a strategic milestone in expanding clinical and commercial uses of its rhCollagen platform in high-value aesthetic markets, highlighting South Korea as one of the company’s largest target territories. The Korean allowance builds on recent Japanese patent protection and complements existing patents in the United States, Europe, China, Brazil, Australia and Israel, strengthening CollPlant’s global IP position as it develops products aimed at a global injectable soft-tissue filler market estimated at more than $6 billion.
The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are built on a proprietary plant-based recombinant human collagen (rhCollagen) platform, targeting tissue repair, aesthetic indications and future organ manufacturing, and it holds a global dermal and soft-tissue filler commercialization agreement with Allergan, an AbbVie company.
Average Trading Volume: 78,128
Technical Sentiment Signal: Sell
Current Market Cap: $8.92M
Find detailed analytics on CLGN stock on TipRanks’ Stock Analysis page.